PreTRM® Test
Risk assessment for spontaneous preterm birth in asymptomatic singleton pregnancies
CommercialMarketed in the U.S.
Key Facts
Indication
Risk assessment for spontaneous preterm birth in asymptomatic singleton pregnancies
Phase
Commercial
Status
Marketed in the U.S.
Company
About Sera Prognostics
Sera Prognostics is a commercial-stage diagnostics company singularly focused on transforming prenatal care through its proprietary proteomic biomarker platform. Its flagship product, the PreTRM® Test, is the first FDA-cleared blood test to provide an individualized risk assessment for spontaneous preterm birth in asymptomatic women. The company's strategy is to drive adoption among providers, payers, and employers by demonstrating improved neonatal outcomes and significant healthcare cost savings, as evidenced by clinical data like the AVERT PRETERM trial. Sera aims to establish itself as a global leader in high-value women's health diagnostics.
View full company profile